Pancreatic ductal adenocarcinoma (PDAC) is a growing medical problem associated with extensive metastasis and high mortality. Intraperitoneal (IP) administration of therapeutics promises to help the treatment of cancers originated from organs in the peritoneal cavity. In this study, we evaluated how physicochemical properties of self-assembled polycation/siRNA nanoparticles affect their IP delivery efficacy in an orthotopic PDAC model. We have examined the effect of covalent polycation modification with lipophobic and hydrophobic tetrafluoro-p-toluic acid (TFTA), hydrophobic cholesterol, and hydrophilic poly(ethylene glycol) respectively. The surface charge of the three different nanoparticles was also modulated by coating the surface with serum albumin. We found that positively charged fluorine-containing particles with lipophobic properties based on a mixture of positively charged polymeric AMD3100 CXCR4 antagonist (PAMD) and PAMD modified with TFTA (mPAMD-TFTA)/siRNA displayed the best cell uptake and transfection efficacy in vitro. Biodistribution evaluation of the nanoparticles in a syngeneic orthotopic PDAC model revealed that the fluorine-containing formulation also achieved the highest PDAC tumor accumulation after IP administration. With a combination of CXCR4 inhibition by PAMD and PLK1 downregulation by siRNA, the treatment with mPAMD-TFTA/siPLK1 showed significant inhibition of both primary and metastatic PDAC tumors. Overall, our study provides insights into and guides the design of the nanoparticles for improved IP delivery of siRNA in PDAC.

Center for Drug Delivery and Nanomedicine Department of Pharmaceutical Sciences University of Nebraska Medical Center Omaha NE 68198 USA

Center for Drug Delivery and Nanomedicine Department of Pharmaceutical Sciences University of Nebraska Medical Center Omaha NE 68198 USA; Institute of Biophysics and Informatics 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Pathology and Microbiology University of Nebraska Medical Center Omaha NE 68198 USA

Zobrazit více v PubMed

Siegel RL, Miller KD, and Jemal A, “Cancer statistics, 2020.” CA: A Cancer Journal for Clinicians, (2020) 70: 7–30. PubMed

Wu W, He X, Yang L, Wang Q, Bian X, Ye J, Li Y, and Li L, “Rising trends in pancreatic cancer incidence and mortality in 2000–2014.” Clinical epidemiology, (2018) 10: 789. PubMed PMC

Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson AB, Mariotto A, Lake AJ, Wilson R, and Sherman RL, “Annual report to the nation on the status of cancer, 1975–2014, featuring survival.” JNCI: Journal of the National Cancer Institute, (2017) 109: djx030. PubMed PMC

Kamisawa T, Wood LD, Itoi T, and Takaori K, “Pancreatic cancer.” The Lancet, (2016) 388: 73–85. PubMed

Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, and Tuveson DA, “The pancreas cancer microenvironment.” Clin Cancer Res, (2012) 18: 4266–76. PubMed PMC

Colombo P-E, Boustta M, Poujol S, Jarlier M, Bressolle F, Teulon I, Ladjemi M-Z, Pinguet F, Rouanet P, and Vert M, “Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer.” Gynecologic oncology, (2011) 122: 632–640. PubMed

Lu Z, Wang J, Wientjes MG, and Au JL, “Intraperitoneal therapy for peritoneal cancer.” Future Oncol, (2010) 6: 1625–41. PubMed PMC

Xie Y, Hang Y, Wang Y, Sleightholm R, Prajapati DR, Bader J, Yu A, Tang W, Jaramillo L, Li J, Singh RK, and Oupicky D, “Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA/siRNA Nanotherapy.” ACS Nano, (2020) 14: 255–271. PubMed PMC

Zhao L, Yuan W, Li J, Yang L, Su Y, Peng J, Chen R, Tham HP, Chen H, and Lim WQ, “Independent of EPR Effect: A Smart Delivery Nanosystem for Tracking and Treatment of Nonvascularized Intra-Abdominal Metastases.” Advanced Functional Materials, (2018) 28: 1806162.

Simón-Gracia L, Hunt H, Scodeller PD, Gaitzsch J, Braun GB, Willmore A-MA, Ruoslahti E, Battaglia G, and Teesalu T, “Paclitaxel-loaded polymersomes for enhanced intraperitoneal chemotherapy.” Molecular cancer therapeutics, (2016) 15: 670–679. PubMed PMC

Gao N, Bozeman EN, Qian W, Wang L, Chen H, Lipowska M, Staley CA, Wang YA, Mao H, and Yang L, “Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.” Theranostics, (2017) 7: 1689–1704. PubMed PMC

Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, and Burger RA, “Intraperitoneal cisplatin and paclitaxel in ovarian cancer.” New England Journal of Medicine, (2006) 354: 34–43. PubMed

Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H, and Zoetmulder FA, “Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.” Journal of clinical oncology, (2003) 21: 3737–3743. PubMed

Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, and Reymond M-A, “Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis.” Journal of Gastrointestinal Surgery, (2016) 20: 367–373. PubMed PMC

Premal HT, William Hampton B, Charles AL, Camille Catherine G, Nicholas B, Lauren M, Khursheed A, and Ronald David A, “Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced-stage ovarian cancer.” J Clin Oncol, (2019) 37: 2–2.

Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, and Au JLS, “Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer.” J Pharmacol Exp Ther, (2008) 327: 673–682. PubMed PMC

Bajaj G and Yeo Y, “Drug delivery systems for intraperitoneal therapy.” Pharm Res, (2010) 27: 735–8. PubMed PMC

Dakwar GR, Shariati M, Willaert W, Ceelen W, De Smedt SC, and Remaut K, “Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis - Mission possible?” Adv Drug Deliv Rev, (2017) 108: 13–24. PubMed

Hargrove D, Liang B, Kashfi-Sadabadi R, Joshi GN, Gonzalez-Fajardo L, Glass S, Jay M, Salner A, and Lu X, “Tumor-mesoporous silica nanoparticle interactions following intraperitoneal delivery for targeting peritoneal metastasis.” J Control Release, (2020). PubMed PMC

Setten RL, Rossi JJ, and Han SP, “The current state and future directions of RNAi-based therapeutics.” Nat Rev Drug Discov, (2019) 18: 421–446. PubMed

Lu D and Thum T, “RNA-based diagnostic and therapeutic strategies for cardiovascular disease.” Nat Rev Cardiol, (2019) 16: 661–674. PubMed

Apparailly F and Jorgensen C, “siRNA-based therapeutic approaches for rheumatic diseases.” Nat Rev Rheumatol, (2013) 9: 56–62. PubMed

Dadashzadeh S, Mirahmadi N, Babaei M, and Vali A, “Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge.” Journal of controlled release, (2010) 148: 177–186. PubMed

Mirahmadi N, Babaei M, Vali A, and Dadashzadeh S, “Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice.” International journal of pharmaceutics, (2010) 383: 7–13. PubMed

Ernsting MJ, Murakami M, Roy A, and Li SD, “Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles.” J Control Release, (2013) 172: 782–94. PubMed PMC

Wang Y, Xie Y, and Oupický D, “Potential of CXCR4/CXCL12 chemokine axis in cancer drug delivery.” Current pharmacology reports, (2016) 2: 1–10. PubMed PMC

Chatterjee S, Azad BB, and Nimmagadda S, The intricate role of CXCR4 in cancer, in Advances in cancer research. 2014, Elsevier. p. 31–82. PubMed PMC

Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ, and Wang J, “CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression.” Cancer and Metastasis Reviews, (2010) 29: 709–722. PubMed PMC

Marechal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, Closset J, Deviere J, Salmon I, and Van Laethem JL, “High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma.” Br J Cancer, (2009) 100: 1444–51. PubMed PMC

Zhang J, Liu C, Mo X, Shi H, and Li S, “Mechanisms by which CXCR4/CXCL12 cause metastatic behavior in pancreatic cancer.” Oncology letters, (2018) 15: 1771–1776. PubMed PMC

Sleightholm RL, Neilsen BK, Li J, Steele MM, Singh RK, Hollingsworth MA, and Oupicky D, “Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy.” Pharmacol Ther, (2017) 179: 158–170. PubMed

Degenhardt Y and Lampkin T, “Targeting Polo-like kinase in cancer therapy.” Clinical cancer research, (2010) 16: 384–389. PubMed

Gutteridge REA, Ndiaye MA, Liu X, and Ahmad N, “Plk1 inhibitors in cancer therapy: from laboratory to clinics.” Molecular cancer therapeutics, (2016) 15: 1427–1435. PubMed PMC

Yim H and Erikson RL, “Plk1-targeted therapies in TP53-or RAS-mutated cancer.” Mutation Research/Reviews in Mutation Research, (2014) 761: 31–39. PubMed

Jones S, Zhang X, Parsons DW, Lin JC-H, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, and Jimeno A, “Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.” science, (2008) 321: 1801–1806. PubMed PMC

Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, and Anderson DG, “Non-viral vectors for gene-based therapy.” Nat Rev Genet, (2014) 15: 541–55. PubMed

Li J, Zhu Y, Hazeldine ST, Li C, and Oupický D, “Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion.” Angewandte Chemie International Edition, (2012) 51: 8740–8743. PubMed PMC

Li J and Oupický D, “Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric Plerixafor.” Biomaterials, (2014) 35: 5572–5579. PubMed PMC

Wang Y, Li J, and Oupicky D, “Polymeric Plerixafor: Effect of PEGylation on CXCR4 Antagonism, Cancer Cell Invasion, and DNA Transfection.” Pharm Res, (2014) 31: 3538–48. PubMed PMC

Wang Y, Li J, Chen Y, and Oupicky D, “Balancing polymer hydrophobicity for ligand presentation and siRNA delivery in dual function CXCR4 inhibiting polyplexes.” Biomater Sci, (2015) 3: 1114–23. PubMed PMC

Wang DA, Narang AS, Kotb M, Gaber AO, Miller DD, Kim SW, and Mahato RI, “Novel branched poly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery.” Biomacromolecules, (2002) 3: 1197–1207. PubMed

Wang M, Liu H, Li L, and Cheng Y, “A fluorinated dendrimer achieves excellent gene transfection efficacy at extremely low nitrogen to phosphorus ratios.” Nature Communications, (2014) 5: 3053. PubMed

Chen G, Wang Y, Wu P, Zhou Y, Yu F, Zhu C, Li Z, Hang Y, Wang K, and Li J, “Reversibly Stabilized Polycation Nanoparticles for Combination Treatment of Early-and Late-Stage Metastatic Breast Cancer.” ACS nano, (2018) 12: 6620–6636. PubMed

Rong G, Wang C, Chen L, Yan Y, and Cheng Y, “Fluoroalkylation promotes cytosolic peptide delivery.” Sci Adv, (2020) 6: eaaz1774. PubMed PMC

Li X, Ma Q, Xu Q, Liu H, Lei J, Duan W, Bhat K, Wang F, Wu E, and Wang Z, “SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial–mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway.” Cancer letters, (2012) 322: 169–176. PubMed PMC

Dakwar GR, Zagato E, Delanghe J, Hobel S, Aigner A, Denys H, Braeckmans K, Ceelen W, De Smedt SC, and Remaut K, “Colloidal stability of nano-sized particles in the peritoneal fluid: towards optimizing drug delivery systems for intraperitoneal therapy.” Acta Biomater, (2014) 10: 2965–75. PubMed

Bienk K, Hvam ML, Pakula MM, Dagnæs-Hansen F, Wengel J, Malle BM, Kragh-Hansen U, Cameron J, Bukrinski JT, and Howard KA, “An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing.” J Control Release, (2016) 232: 143–151. PubMed

Kratz F, “A clinical update of using albumin as a drug vehicle—A commentary.” Journal of controlled release, (2014) 190: 331–336. PubMed

Wang H-X, Zuo Z-Q, Du J-Z, Wang Y-C, Sun R, Cao Z-T, Ye X-D, Wang J-L, Leong KW, and Wang J, “Surface charge critically affects tumor penetration and therapeutic efficacy of cancer nanomedicines.” Nano Today, (2016) 11: 133–144.

Liu X and Erikson RL, “Polo-like kinase (Plk) 1 depletion induces apoptosis in cancer cells.” Proceedings of the National Academy of Sciences, (2003) 100: 5789–5794. PubMed PMC

Dadashzadeh S, Mirahmadi N, Babaei MH, and Vali AM, “Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge.” J Control Release, (2010) 148: 177–86. PubMed

Mirahmadi N, Babaei MH, Vali AM, and Dadashzadeh S, “Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice.” Int J Pharm, (2010) 383: 7–13. PubMed

Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Röhl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, and Vornlocher H-P, “Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.” Nature, (2004) 432: 173–178. PubMed

Dykxhoorn DM and Lieberman J, “Knocking down Disease with siRNAs.” Cell, (2006) 126: 231–235. PubMed PMC

Colby AH, Berry SM, Moran AM, Pasion KA, Liu R, Colson YL, Ruiz-Opazo N, Grinstaff MW, and Herrera VL, “Highly Specific and Sensitive Fluorescent Nanoprobes for Image-Guided Resection of Sub-Millimeter Peritoneal Tumors.” ACS Nano, (2017) 11: 1466–1477. PubMed PMC

Hirano K, Hunt CA, Strubbe A, and MacGregor RD, “Lymphatic transport of liposome-encapsulated drugs following intraperitoneal administration–effect of lipid composition.” Pharmaceutical research, (1985) 2: 271–278. PubMed

Yanez JA, Wang SW, Knemeyer IW, Wirth MA, and Alton KB, “Intestinal lymphatic transport for drug delivery.” Adv Drug Deliv Rev, (2011) 63: 923–42. PubMed PMC

Alizadeh D, Zhang L, Schluep T, and Badie B, “Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas.” Nanomedicine: Nanotechnology, Biology and Medicine, (2010) 6: 382–390. PubMed PMC

Wayne EC, Long C, Haney MJ, Batrakova EV, Leisner TM, Parise LV, and Kabanov AV, “Targeted Delivery of siRNA Lipoplexes to Cancer Cells Using Macrophage Transient Horizontal Gene Transfer.” Advanced Science, (2019) 6: 1900582. PubMed PMC

Chen G, Wang Y, Wu P, Zhou Y, Yu F, Zhu C, Li Z, Hang Y, Wang K, Li J, Sun M, and Oupicky D, “Reversibly Stabilized Polycation Nanoparticles for Combination Treatment of Early- and Late-Stage Metastatic Breast Cancer.” ACS Nano, (2018) 12: 6620–6636. PubMed

Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, Ren L, Wong D, Korz W, and Merzouk A, “Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases.” Clinical & experimental metastasis, (2008) 25: 201–211. PubMed PMC

Advances in Liposome-Encapsulated Phthalocyanines for Photodynamic Therapy